As a specialist Nutritional Therapist and Health Coach, my role is to help you make sense of that complexity, identify what works for you, and build sustainable changes that support your health long term
It prevents the acidity of the ACV from interfering with the delicate glutathione molecule and ensures your digestion is primed for your first meal of the day
GHK-Cu is not FDA approved as a drug for skin repair, anti-aging, injection, or any therapeutic use, and researchers exploring administration should review our guide on where to inject GHK-Cu for the practical considerations
: JAMA Psychiatry study highlights (semaglutide in schizophrenia spectrum disorders): Studied adults with schizophrenia spectrum disorders treated with clozapine or olanzapine, two antipsychotics strongly linked to weight gain and metabolic syndrome Participants were randomized to receive semaglutide (GLP-1 receptor agonist) vs placebo, in addition to usual psychiatric care Significant weight loss was observed in the semaglutide group compared with placebo Improved glycemic control including reductions in HbA1c and fasting glucose, even in early metabolic dysregulation Beneficial effects seen early, suggesting potential for prevention of diabetes rather than late treatment Semaglutide was generally well tolerated, with no worsening of psychotic symptoms Addresses a major unmet need, people with serious mental illness die earlier largely due to cardiometabolic disease Supports the role of GLP-1 receptor agonists as an adjunct treatment to mitigate antipsychotic-induced metabolic harm Bottom line: A promising strategy to reduce weight, diabetes risk, and long-term cardiovascular mortality in patients on high-risk antipsychotics
